<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00656175</url>
  </required_header>
  <id_info>
    <org_study_id>IISP-Raltegravir</org_study_id>
    <nct_id>NCT00656175</nct_id>
    <nct_alias>NCT00755612</nct_alias>
  </id_info>
  <brief_title>Raltegravir Therapy for Women With HIV and Fat Accumulation</brief_title>
  <official_title>Phase II Study of Raltegravir as Replacement for Protease Inhibitor or Non-Nucleoside Reverse Transcriptase Inhibitor (NNRTI) Based Antiretroviral Therapy in Women With Fat Accumulation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of California, Los Angeles</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>Merck Sharp &amp; Dohme Corp.</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
    <collaborator>
      <agency>Case Western Reserve University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Vanderbilt University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>Tufts University</agency>
      <agency_class>Other</agency_class>
    </collaborator>
    <collaborator>
      <agency>University Health Network, Toronto</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>University of California, Los Angeles</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Ritonavir-boosted protease inhibitor (PI) regimens have become a backbone for treatment of
      people with HIV. However, adverse drug effects, particularly lipodystrophy/lipoatrophy are
      closely associated with these regimens. Therefore, there is a need for a drug with comparable
      effectiveness to the ritonavir boosted PIs without the side effects of dyslipidemia, which
      has been associated with elevated cholesterol and cardiovascular disease

      Raltegravir is an HIV integrase inhibitor in phase III clinical development. To date there
      are no approved drugs that target the same stage of the HIV-1 lifecycle. However, data from
      studies indicate that raltegravir is generally safe and well tolerated and has strong
      antiretroviral activity when used in combination with licensed antiretroviral medications.

      This study aims to demonstrate that patients substituting raltegravir for a PI or NNRTI based
      antiretroviral regimen will be associated with a 10% reduction in body fat over 24 weeks.

      The study will consist of a total of 10 subject visits over a period of 48 weeks.
      Approximately 40 female patients will participate in this study (approximately 10 at UCLA).
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>September 2008</start_date>
  <completion_date type="Actual">December 2011</completion_date>
  <primary_completion_date type="Actual">December 2011</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Baseline to 24-week Change in Visceral Adipose Tissue Volume (cm^2)</measure>
    <time_frame>Baseline and 24 weeks</time_frame>
    <description>Adipose tissue volumes were measured via single slice L4-L5 CT scan, and volumes were calculated using cm^2, not cm^3, as is standard protocol at the Tufts University Body Composition Reading Center. The authors acknowledge that cm^2 uses area as a surrogate for volume, but this protocol is well-accepted in our field.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">39</enrollment>
  <condition>HIV Infections</condition>
  <condition>Lipodystrophy</condition>
  <arm_group>
    <arm_group_label>Immediate</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Immediate switch of PI or NNRTI to Raltegravir</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Delayed</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Continue current therapy unchanged for 24 weeks, then switch PI or NNRTI to Raltegravir</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>raltegravir</intervention_name>
    <description>raltegravir</description>
    <arm_group_label>Immediate</arm_group_label>
    <arm_group_label>Delayed</arm_group_label>
    <other_name>Isentress</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  HIV-1 infection as documented by any licensed ELISA test kit and confirmed by Western
             blot at any time prior to study entry or plasma HIV-1 RNA &gt; 2000 on two occasions,

          -  Female subjects 18 years or older

          -  Documented central fat accumulation (defined by waist circumference of &gt; 94 cm or a
             waist to hip ratio of &gt; 0.88).

          -  Documented HIV RNA &lt;50 copies/mL at screening and &lt;400 copies/mL in the past 6 months.

          -  Current antiretroviral therapy with two nucleoside analogues and either a
             non-nucleoside analogue (nevirapine, efavirenz or TMC125) or an approved protease
             inhibitor. Patients on NNRTI+PI at study entry will be excluded. Study participants do
             not need to be on their first regimen. No changes in ART in the 12 weeks prior to
             screening. The nucleoside backbone must include either tenofovir or abacavir and
             either lamivudine or emtricitabine. Fixed dose combinations with emtricitabine or
             abacavir are allowed.

          -  For females of reproductive potential (women who have not been post-menopausal for at
             least 24 consecutive months, i.e., who have had menses within the preceding 24 months,
             or women who have not undergone surgical sterilization, specifically hysterectomy, or
             bilateral oophorectomy and/or tubal ligation), will need a negative serum or urine
             pregnancy test within 48 hours prior to entry.

          -  Ability and willingness of subject to provide informed consent.

        Exclusion Criteria:

          -  Pregnancy: current or within the past 6 months or breast feeding

          -  Prior treatment history that would preclude the use of emtricitabine or abacavir as
             the nucleoside backbone during study treatment

          -  Current use of metformin or thiazolidinediones.

          -  Use of growth hormone or growth hormone releasing factor in the last 6 months before
             screening.

          -  Change or initiation of anti-hyperlipemic regimen within 3 months prior to
             randomization; Use of stable anti-hyperlipemic regimen during the study is allowed.

          -  Current use of androgen therapy.

          -  Intent to modify diet, exercise habits or to enroll in a weight loss intervention
             during the study period.

          -  Current or projected need to use rifampin, dilantin or phenobarbital during the
             48-week study period.

          -  Laboratory values at screening of

               -  ANC &gt;500 cells/mm3

               -  Hemoglobin &lt;10 gm/dl

               -  CrCl &gt; 60 ml/min (estimated by Cockcroft-Gault equation)

               -  AST or ALT &gt; 3 x ULN
      </textblock>
    </criteria>
    <gender>Female</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Judith S. Currier, M.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of California, Los Angeles</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Grace McComsey, M.D.</last_name>
    <role>Study Chair</role>
    <affiliation>Case School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>UCLA CARE Center</name>
      <address>
        <city>Los Angeles</city>
        <state>California</state>
        <zip>90035</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tufts University School of Medicine</name>
      <address>
        <city>Boston</city>
        <state>Massachusetts</state>
        <zip>02111</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Case School of Medicine</name>
      <address>
        <city>Cleveland</city>
        <state>Ohio</state>
        <zip>44106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Vanderbilt University</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Health Network, Toronto</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <results_reference>
    <citation>Lake JE, McComsey GA, Hulgan TM, Wanke CA, Mangili A, Walmsley SL, Boger MS, Turner RR, McCreath HE, Currier JS. A randomized trial of Raltegravir replacement for protease inhibitor or non-nucleoside reverse transcriptase inhibitor in HIV-infected women with lipohypertrophy. AIDS Patient Care STDS. 2012 Sep;26(9):532-40. doi: 10.1089/apc.2012.0135. Epub 2012 Jul 23.</citation>
    <PMID>22823027</PMID>
  </results_reference>
  <verification_date>December 2012</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>April 2, 2008</study_first_submitted>
  <study_first_submitted_qc>April 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 10, 2008</study_first_posted>
  <results_first_submitted>June 12, 2012</results_first_submitted>
  <results_first_submitted_qc>December 17, 2012</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 19, 2012</results_first_posted>
  <last_update_submitted>December 17, 2012</last_update_submitted>
  <last_update_submitted_qc>December 17, 2012</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 19, 2012</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of California, Los Angeles</investigator_affiliation>
    <investigator_full_name>Judith S. Currier</investigator_full_name>
    <investigator_title>M.D.</investigator_title>
  </responsible_party>
  <keyword>lipodystrophy</keyword>
  <keyword>fat</keyword>
  <keyword>visceral fat</keyword>
  <keyword>HIV</keyword>
  <keyword>women</keyword>
  <keyword>raltegravir</keyword>
  <keyword>ART</keyword>
  <keyword>anti HIV therapy</keyword>
  <keyword>NNRTI</keyword>
  <keyword>Protease inhibitor</keyword>
  <keyword>integrase inhibitor</keyword>
  <keyword>treatment experienced</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>HIV Infections</mesh_term>
    <mesh_term>Lipodystrophy</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Raltegravir Potassium</mesh_term>
    <mesh_term>Protease Inhibitors</mesh_term>
    <mesh_term>HIV Protease Inhibitors</mesh_term>
    <mesh_term>Reverse Transcriptase Inhibitors</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <recruitment_details>61 subjects were screened, 39 enrolled, and 37 completed the Week 24 primary endpoint at 5 sites in North America.
Of the 37 subjects included in the as-treated analysis, 17 were randomized to immediate-switch (Immediate Group), and 20 to delayed-switch (Delayed Group).</recruitment_details>
      <group_list>
        <group group_id="P1">
          <title>Immediate</title>
          <description>Immediate switch of PI or NNRTI to Raltegravir (400 mg twice daily)</description>
        </group>
        <group group_id="P2">
          <title>Delayed</title>
          <description>Continue current therapy unchanged for 24 weeks, then switch PI or NNRTI to Raltegravir (400mg twice daily)</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="21"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="17"/>
                <participants group_id="P2" count="20"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </drop_withdraw_reason>
            <drop_withdraw_reason>
              <title>Transportation issues</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Immediate</title>
          <description>Immediate switch of PI or NNRTI to Raltegravir</description>
        </group>
        <group group_id="B2">
          <title>Delayed</title>
          <description>Continue current therapy unchanged for 24 weeks then switch PI or NNRTI to Raltegravir</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="18"/>
            <count group_id="B2" value="21"/>
            <count group_id="B3" value="39"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>&lt;=18 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Between 18 and 65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>&gt;=65 years</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="39" spread="47"/>
                    <measurement group_id="B2" value="36" spread="51"/>
                    <measurement group_id="B3" value="37" spread="49"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Gender</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>Female</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Male</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race/Ethnicity, Customized</title>
          <description>Subjects were recruited from 5 centers in North America between September 2008 and July 2010. Age 18 or older, documented HIV-1 infection, central fat accumulation at screening and &lt;400 copies/mL for the 6 months prior to entry, current ART with a nucleoside (NRTI) backbone of tenofovir or abacavir AND emtricitabine or lamivudine PLUS either a PI or NNRTI, no change in ART for 12 weeks prior to screening, and ability and willingness to provide informed consent.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>African-American</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="22"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Hispanic</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>White</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="8" lower_limit="24"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Asian</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <description>Subjects were recruited from 5 centers in North America between September 2008 and July 2010.</description>
          <units>Participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>North America</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="18"/>
                    <measurement group_id="B2" value="21"/>
                    <measurement group_id="B3" value="39"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Baseline to 24-week Change in Visceral Adipose Tissue Volume (cm^2)</title>
        <description>Adipose tissue volumes were measured via single slice L4-L5 CT scan, and volumes were calculated using cm^2, not cm^3, as is standard protocol at the Tufts University Body Composition Reading Center. The authors acknowledge that cm^2 uses area as a surrogate for volume, but this protocol is well-accepted in our field.</description>
        <time_frame>Baseline and 24 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Immediate</title>
            <description>Immediate switch of PI or NNRTI to Raltegravir</description>
          </group>
          <group group_id="O2">
            <title>Delayed</title>
            <description>Continue current therapy unchanged for 24 weeks, then switch PI or NNRTI to Raltegravir</description>
          </group>
        </group_list>
        <measure>
          <title>Baseline to 24-week Change in Visceral Adipose Tissue Volume (cm^2)</title>
          <description>Adipose tissue volumes were measured via single slice L4-L5 CT scan, and volumes were calculated using cm^2, not cm^3, as is standard protocol at the Tufts University Body Composition Reading Center. The authors acknowledge that cm^2 uses area as a surrogate for volume, but this protocol is well-accepted in our field.</description>
          <units>cm^2</units>
          <param>Median</param>
          <dispersion>Inter-Quartile Range</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="17"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-6.6" lower_limit="-15.5" upper_limit="17.6"/>
                    <measurement group_id="O2" value="1.8" lower_limit="-9.3" upper_limit="8.1"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <groups_desc>Wilcoxon sign-rank test used for statistical significance.</groups_desc>
            <non_inferiority_type>Superiority or Other</non_inferiority_type>
            <p_value>0.52</p_value>
            <method>Wilcoxon (Mann-Whitney)</method>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Immediate</title>
          <description>Immediate switch of PI or NNRTI to Raltegravir</description>
        </group>
        <group group_id="E2">
          <title>Delayed</title>
          <description>Continue current therapy unchanged for 24 weeks then switch PI or NNRTI to Raltegravir</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="17"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="20"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>All Principal Investigators ARE employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <limitations_and_caveats>High prevalence of generalized obesity; small sample size; short follow-up; not designed to assess the potential contribution of NRTIs to lipohypertrophy, nor could we exclude the NRTI backbone as a confounding factor.</limitations_and_caveats>
    <point_of_contact>
      <name_or_title>Dr. Jordan Lake</name_or_title>
      <organization>UCLA CARE Center</organization>
      <phone>310-557-9679</phone>
      <email>jlake@mednet.ucla.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

